6,678 trials
Bacterial Vaginosis
Primary: Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests — 5.59; 5.22; 4.91; 7.41 log10 copies/ml — p=0.011
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Deaths — 106; 1; 0…
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Opioid Use · Enhanced Recovery After Surgery · Anesthesia
Primary: Length of Stay — 5.0; 5.0 days
Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (DBP) Between Visit 2 (Week 0) and Visit 4 (Week 8) — -15.2 mmHg — p=<0.001
Erectile Dysfunction
Primary: Visual-analogue Pain Scale — 6; 4 units on a scale
Multiple Sclerosis · Fatigue · Insomnia
Primary: Change in Insomnia Severity Index (ISI) Score — -4; -2 score on a scale
Obstruction · Cancer · Ileus
Primary: Prealbumin — 0.15; 0.16 g/l
Osteoarthritis · Osteo Arthritis Knee
Primary: Change in Visual Analog Scale (VAS) Pain Score — -1.45; -1.16 score on a scale
Neoplasm Metastasis / Bone and Bones
Primary: Number of Participants With Radium-223 Dichloride-/Placebo-related Adverse Events (AEs) — 0; 1; 1; 0 Participants
Carcinoma · Carcinoma, Hepatocellular · Liver Neoplasm
Primary: Mean Absorbed Dose (Gy) for the Whole Body — 0.941 mGy
CYP2D6 Polymorphism
Primary: CYP2D6 Activity as Measured by the Molar Concentration Ratio of Dextromethorphan (DM)/Dextrophan (DX) — 16.0; 12.5 Ratio
Withdrawal; Therapeutic Substance
Primary: Number of Participants With Withdrawal — 33; 10 Participants
Age-related Macular Degeneration
Primary: Week 40 to Week 52: LS Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 3.24; -0.50; 3.88; -0.27 Letters read
Opioid Substitution Treatment
Primary: POD1 Visual Analog Pain (VAS) Score — 5.8; 5 Score on a scale — p=.16